ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12615000079549

Ethics application status

Approved

Date submitted

9/01/2015

Date registered

30/01/2015

Date last updated

30/01/2015

Type of registration

Retrospectively registered

Titles & IDs

Public title

Early detection of lung disease in smokers with normal spirometry

Scientific title

Multiple breath nitrogen washout (MBNW) and impulse oscillometry system (IOS) to detect small airway disease in smokers with normal spirometry

Secondary ID [1]

Nil

Universal Trial Number (UTN)

U1111-1165-8083

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Chronic Obstructive Pulmonary Disease

Condition category

Condition code

Respiratory

Chronic obstructive pulmonary disease

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

There will be one (1) visit for this study which will either take place at the Woolcock Institute of Medical Research or at the Respiratory Investigation Unit at Royal North Shore Hospital. The visit will last around 90 minutes. All tests that we will administer are used routinely for lung function testing in hospital lung function laboratories in Australia and internationally.

We will perform an allergy test called a skin prick test. A small droplet of allergen will be placed on subject's forearm and the skin will be pricked lightly through the droplet. If subject is allergic to any of the allergens you will develop a small itchy lump, like a mosquito bite.

Subject's lung size will be measured in a body plethysmograph. This requires sitting in a clear Perspex booth during which subject will be asked to breathe on a mouth piece.Subject will be asked to breathe at different speeds and to take in a slow deep breath and then breathe out slowly and push all the air out of your lungs. The whole test will take approximately 15 minutes.

Two types of simple breathing tests will be conducted to measure how efficient subject's lungs are at moving air in and out. For the first test, known as spirometry, subject will be asked to take a deep breath and blow as hard and fast as you can for as long as you can into the mouthpiece. This manoeuvre will be repeated three times, and will take five minutes. For the second test, subject will be asked to breathe quietly on a mouthpiece for one minute while wearing a nose clip. Subject will feel a slight “flutter” in the air that he will breathe during this test, but it will not cause any discomfort.

A washout test will tell us how evenly air is distributed throughout the lungs. Subject will breathe into a mouthpiece, keeping the size of your breaths within a set range. During the test you will first breathe normal room air and then 100% oxygen for approximately 20 breaths. Each test is performed 3 times and it takes about 20-25 minutes to complete all three tests.
All the measurements will be made before and 20 minutes after inhalation of 200microgram of salbutamol (2 puffs) and 80 microgram of ipratropium bromide (4 puffs) via metered dose inhaler and large volume spacer in smokers with normal spirometry.

Intervention code [1]

Early detection / Screening

Comparator / control treatment

Spirometry, body plethysmography, single-breath diffusing capacity for carbon monoxide (DLCO), MBNW and IOS measurements will be made before and 20 minutes after inhalation of 200microgram of salbutamol and 80 microgram of ipratropium bromide via metered dose inhaler and large volume spacer in never smokers with normal spirometry.

Control group

Active

Outcomes

Primary outcome [1]

Calculate the sensitivity and specificity of impulse oscillometry technique (IOS) and multiple breath nitrogen washout technique (MBNW) in detection of smoking induced peripheral airway altercation in smokers with normal spirometry
The reference values for IOS will be those of Newbury et al and values for spirometry will be those of Quanjer et al. We will use receiver operator curve (ROC) analysis to determine the specificity and sensitivity for IOS parameters to detect small airways disease, defined as abnormal Sacin or Scond. We will also compare the proportions of subjects who have abnormal values for IOS and MBNW using chi-square analyses. Relationships with smoking history will be examined using correlation analyses.
non smokers will not be included in this analaysis

Timepoint [1]

The outcome will be measured after all the data has been collected for smokers with normal spirometry.

Secondary outcome [1]

To determine whether abnormalities in Sacin and Scond (measured using MBNW) and resistance and reactance (measured using IOS) in smokers with normal spirometry were normalised by inhalation of short acting beta agonist and anti-cholinergic.

Timepoint [1]

The response will be measured after acute administration of bronchodilator (after 20 minutes of administration).
The improvement in Sacin and Scond and resistance and reactance in smokers will be compared against non smokers. Bronchodilator response and differences between groups were examined using t-tests, Mann–Whitney-U tests or Kruskal-Wallis and post hoc Dunn-Bonferroni tests as appropriate. Correlations were examined using Spearman correlation coefficients.

Eligibility

Key inclusion criteria

Smokers with greater than equal to 10 Pack years of smoking history and Normal spirometry defined as FEV1> 80% predicted and FEV1/FVC greater than 0.70
Non smokers with Normal spirometry defined as FEV1> 80% predicted and FEV1/FVC greater than 0.70

Minimum age

18 Years

Maximum age

65 Years

Sex

Both males and females

Can healthy volunteers participate?

Yes

Key exclusion criteria

Any history of respiratory disease or cardiovascular disease.
Women who are pregnant
People who are unable to understand the patient information statement
Same criteria for never smokers will be included

Study design

Purpose of the study

Diagnosis

Allocation to intervention

Non-randomised trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Who is / are masked / blinded?

Intervention assignment

Other design features

Phase

Not Applicable

Type of endpoint/s

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Date of first participant enrolment

Anticipated

1/05/2012

Actual

21/05/2012

Date of last participant enrolment

Anticipated

Actual

20/09/2013

Date of last data collection

Anticipated

Actual

Sample size

Target

100

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

NSW

Recruitment hospital [1]

Royal North Shore Hospital - St Leonards

Funding & Sponsors

Funding source category [1]

Commercial sector/Industry

Name [1]

GlaxoSmithKline

Address [1]

Level 4, 436 Johnston Street, Abbotsford, Victoria, 3067, Australia

Country [1]

Australia

Primary sponsor type

Individual

Name

Kanika Jetmalani

Address

Woolcock Institute of Medical Research
431 Glebe point Road, Glebe, NSW, 2037

Country

Australia

Secondary sponsor category [1]

Individual

Name [1]

A/Prof. Gregory King

Address [1]

Woolcock Institute of Medical Research
431 Glebe point Road, Glebe, NSW, 2037
Department of Respiratory Medicine
Royal North Shore Hospital
Pacific Highway
St Leonards, NSW, 2065

Country [1]

Australia

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Northern Sydney Central Coast Area Health Service Human Research Ethics Committee

Ethics committee address [1]

Research Office
Royal North Shore Hospital
St. Leonards, NSW, 2065

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

Approval date [1]

28/11/2011

Ethics approval number [1]

Summary

Brief summary

In chronic obstructive pulmonary disease (COPD), commonly associated with long term smoking, the earliest abnormality occurs in the very small airways. However, these changes to the small airways are unable to be detected by common lung function tests used in clinical practice and therefore early detection of COPD at present is impossible. In our laboratory we have two easy-to-perform lung function tests that are sensitive to abnormalities in the small airways and we want to determine whether these tests are able to detect abnormalities when common lung function tests remain normal and if they can be treated with administration of bronchodilators. If either of these tests are sensitive to small airway abnormalities it will mean that they have the potential to be used for the early detection of COPD in smokers.   

We hypothesise that IOS parameters will be sensitive to alterations in small airway function, as defined by
abnormal ventilation heterogeneity measured by MBNW, in smokers with normal spirometry. Also, these abnormalities may be partially of completely reversed with bronchodilators.

Trial website

Trial related presentations / publications

1. K Jetmalani, A Bertolin, CS Farah, NJ Brown, N Berend, CM Salome, GG King (2014), Can impulse oscillometry detect peripheral airway abnormalities measured using multiple breath nitrogen washout (MBNW) in asymptomatic smokers? Am J Respir Crit Care Med. 189 (meeting abstracts), P: A3547.
2. K Jetmalani, CS Farah, NJ Brown, N Berend, CM Salome, GG King (2014), Is increased bronchomotor tone an important driving factor in developing acinar airway abnormalities in smokers with normal spirometry? Respirology. 19 suppl. 2. P: 2-6.
3. K Jetmalani, CS Farah, NJ Brown, N Berend, CM Salome, GG King (2013), Small airway function in smokers with normal spirometry improves with bronchodilator. Am J Respir Crit Care Med. 187 (meeting abstracts), P: A1934.
4. K Jetmalani, D Chapman, CS Farah, NJ Brown, N Berend, CM Salome, GG King (2013), Role of bronchomotor tone in developing acinar airway abnormalities in smokers with normal spirometry. Proceedings of XIIIth Annual Bosch Young Investigator Symposium. P: 21
5. K Jetmalani, CS Farah, NJ Brown, N Berend, CM Salome, GG King (2013), Abnormal airway function in smokers with normal spirometry. Respirology. 18 suppl. 2. P: 4.
6. K Jetmalani, CS Farah, NJ Brown, N Berend, CM Salome, GG King (2013), Small airway function in smokers with normal spirometry improves with bronchodilator. Respirology. 18 suppl. 2. P: 20.

Public notes

Contacts

Principal investigator

Name

Miss Kanika Jetmalani

Address

Woolcock Institute of Medical Research
431 Glebe Point Road, Glebe
NSW 2037

Country

Australia

Phone

+61291140147

Fax

kanika.jetmalani@sydney.edu.au

Contact person for public queries

Name

Kanika Jetmalani

Address

Woolcock Institute of Medical Research
431 Glebe point Road, Glebe, NSW, 2037

Country

Australia

Phone

+61291140147

Fax

kanika.jetmalani@sydney.edu.au

Contact person for scientific queries

Name

Kanika Jetmalani

Address

Woolcock Institute of Medical Research
431 Glebe point Road, Glebe, NSW, 2037

Country

Australia

Phone

+61291140147

Fax

kanika.jetmalani@sydney.edu.au

No information has been provided regarding IPD availability

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

Source	Title	Year of Publication	DOI
Embase	Bronchodilator responsiveness of peripheral airways in smokers with normal spirometry.	2016	https://dx.doi.org/10.1111/resp.12802

N.B. These documents automatically identified may not have been verified by the study sponsor.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically